AU2012332176B2 - Pharmaceutical compositions of hydrophobic camptothecin derivatives - Google Patents

Pharmaceutical compositions of hydrophobic camptothecin derivatives Download PDF

Info

Publication number
AU2012332176B2
AU2012332176B2 AU2012332176A AU2012332176A AU2012332176B2 AU 2012332176 B2 AU2012332176 B2 AU 2012332176B2 AU 2012332176 A AU2012332176 A AU 2012332176A AU 2012332176 A AU2012332176 A AU 2012332176A AU 2012332176 B2 AU2012332176 B2 AU 2012332176B2
Authority
AU
Australia
Prior art keywords
lower alkyl
alkyl
amino
residue
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012332176A
Other languages
English (en)
Other versions
AU2012332176A1 (en
Inventor
Yung-Hsu Chan
Keelung Hong
Chiahung Hung
Pei Kan
Yun-Long Tseng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Original Assignee
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, TLC Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of AU2012332176A1 publication Critical patent/AU2012332176A1/en
Application granted granted Critical
Publication of AU2012332176B2 publication Critical patent/AU2012332176B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012332176A 2011-11-03 2012-11-02 Pharmaceutical compositions of hydrophobic camptothecin derivatives Ceased AU2012332176B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555084P 2011-11-03 2011-11-03
US61/555,084 2011-11-03
PCT/US2012/063447 WO2013067449A1 (en) 2011-11-03 2012-11-02 Pharmaceutical compositions of hydrophobic camptothecin derivatives

Publications (2)

Publication Number Publication Date
AU2012332176A1 AU2012332176A1 (en) 2014-01-16
AU2012332176B2 true AU2012332176B2 (en) 2016-03-10

Family

ID=48192863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012332176A Ceased AU2012332176B2 (en) 2011-11-03 2012-11-02 Pharmaceutical compositions of hydrophobic camptothecin derivatives

Country Status (12)

Country Link
US (1) US10391056B2 (enExample)
EP (1) EP2773346B1 (enExample)
JP (1) JP6205095B2 (enExample)
KR (1) KR101688898B1 (enExample)
CN (1) CN103957912B (enExample)
AU (1) AU2012332176B2 (enExample)
CA (1) CA2850955C (enExample)
IN (1) IN2014DN00277A (enExample)
SG (1) SG10201609199YA (enExample)
TW (3) TWI619496B (enExample)
WO (1) WO2013067449A1 (enExample)
ZA (1) ZA201403195B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
TWI526446B (zh) * 2013-09-27 2016-03-21 中國醫藥大學附設醫院 喜樹鹼的新穎２０（ｓ）－磺基脒衍生物及其抗腫瘤劑的用途
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
KR102664243B1 (ko) * 2018-01-19 2024-05-08 데루타-후라이 화마 가부시키가이샤 암 환자의 치료에 유용한 오줌의 알칼리제
CN111632144B (zh) * 2020-07-06 2022-07-29 聊城大学 一种高载药量的光-化疗双功能纳米粒及其制备方法
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
KR20250079213A (ko) 2022-10-09 2025-06-04 라노바 메디신즈 리미티드 화합물, 조성물 및 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN102018670A (zh) * 2010-11-15 2011-04-20 宜昌人福药业有限责任公司 一种抗癌制剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU2001258106A1 (en) 2000-05-11 2001-11-20 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
US7485320B2 (en) * 2000-09-25 2009-02-03 Industrial Technology Research Institute Liposome for incorporating large amounts of hydrophobic substances
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
NZ551748A (en) 2004-06-01 2010-02-26 Yakult Honsha Kk Irinotecan formulation
WO2005123078A1 (ja) * 2004-06-18 2005-12-29 Terumo Kabushiki Kaisha 水難溶性カンプトテシン含有リポソーム製剤
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US20080213385A1 (en) 2005-08-10 2008-09-04 Oskar Kalb Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
AU2008210511A1 (en) 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
US8168648B2 (en) 2009-03-06 2012-05-01 Taiwan Liposome Co., Ltd. Camptothecin derivatives and uses thereof
CN101869712B (zh) 2009-04-21 2016-01-20 财团法人工业技术研究院 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物
US20140135357A1 (en) 2012-11-12 2014-05-15 Taiwan Liposome Company, Ltd. Dose regime for camptothecin derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物
CN102018670A (zh) * 2010-11-15 2011-04-20 宜昌人福药业有限责任公司 一种抗癌制剂及其制备方法

Also Published As

Publication number Publication date
ZA201403195B (en) 2020-05-27
WO2013067449A1 (en) 2013-05-10
TWI619496B (zh) 2018-04-01
CA2850955C (en) 2019-11-19
EP2773346B1 (en) 2021-10-27
SG10201609199YA (en) 2016-12-29
KR101688898B1 (ko) 2016-12-22
AU2012332176A1 (en) 2014-01-16
EP2773346A4 (en) 2015-08-19
EP2773346A1 (en) 2014-09-10
CN103957912A (zh) 2014-07-30
CN103957912B (zh) 2019-04-05
US20140294973A1 (en) 2014-10-02
NZ620933A (en) 2016-05-27
CA2850955A1 (en) 2013-05-10
US10391056B2 (en) 2019-08-27
TWI480042B (zh) 2015-04-11
KR20140057384A (ko) 2014-05-12
JP2014532727A (ja) 2014-12-08
TW201513865A (zh) 2015-04-16
TW201637654A (zh) 2016-11-01
JP6205095B2 (ja) 2017-09-27
TW201325591A (zh) 2013-07-01
IN2014DN00277A (enExample) 2015-06-05
TWI549679B (zh) 2016-09-21

Similar Documents

Publication Publication Date Title
EP2773346B1 (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
Yang et al. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer
Chung et al. A multi-functional PEGylated gold (iii) compound: potent anti-cancer properties and self-assembly into nanostructures for drug co-delivery
US9814734B2 (en) Bufalin liposome, preparation method therefor and application thereof
ES2665033T3 (es) Liposoma que tiene una fase acuosa interna que contiene sal de sulfobutil éter ciclodextrina
CN101138550B (zh) 多种表面活性剂联合使用制备的混合胶束药物制剂及其制备方法
JP4990786B2 (ja) 薬物リポソーム製剤を安定化するための組成物および方法
US11357728B2 (en) Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
ES2428088T3 (es) Derivados de camptotecina como agentes quimioradiosensibilizadores
Zhang et al. Engineering a pH‐responsive polymeric micelle co‐loaded with paclitaxel and triptolide for breast cancer therapy
CN102697795A (zh) 一种抗肿瘤联合用药物
CN103442565B (zh) 使用用于癌症治疗的化合物fl118制剂的非水溶性化合物新型制剂及方法
CN104083325B (zh) 一种盐酸伊立替康纳米脂束制剂及其制备方法
US10980798B2 (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
CN107007550A (zh) 一种氧化还原响应性两亲性共聚物及其制备方法和应用
NZ620933B2 (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
HK1196556B (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
CN105797169A (zh) 一种抗肿瘤大分子前药复合物及其制备方法和应用
HK1196556A (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
Zhang et al. Engineering a pH-responsive polymeric micelle co-loaded with paclitaxel and tretinoin for breast cancer therapy
CN119236093A (zh) 一种前体纳米自组装免疫组合物及其制备方法和应用
Radosz et al. Breast Cancer-Targeted Nuclear Drug Delivery Overcoming Drug Resistance for Breast Cancer Chemotherapy
CN102048697A (zh) 一种水溶性抗肿瘤药物固体脂质纳米粒的制备方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KAN, PEI; HUNG, CHIAHUNG; HONG, KEELUNG; TSENG, YUN-LONG AND CHAN, YUNG-HSU

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired